問卷

TPIDB > Search Result

Search Result

篩選

List

1449Cases

2023-08-31 - 2032-02-12

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2025-09-01 - 2029-12-31

Phase III

Active
A Multicenter, Long-term, Randomized, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants with Sjögren’s Syndrome (SS)
  • Condition/Disease

    Sjögren’s Syndrome (SS)

  • Test Drug

    Injection

Participate Sites
5Sites

Recruiting5Sites

2018-06-08 - 2021-01-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2025-07-01 - 2030-10-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-06-30 - 2030-12-31

Phase III

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
7Sites

Recruiting7Sites

2023-03-01 - 2028-10-16

Phase III

Active
An Expanded Access Program of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria

  • Test Drug

    PozelimabCemdisiran

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2025-05-30 - 2027-07-12

Phase III

Active
SYNOVIIIUS: Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients with Hemophilia A
  • Condition/Disease

    Hemophilia A

  • Test Drug

    Lyophilized powder for injection Lyophilized powder for injection Lyophilized powder for injection Lyophilized powder for injection Lyophilized powder for injection

Participate Sites
3Sites

Recruiting3Sites

2021-08-01 - 2029-02-28

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-03-10 - 2024-11-14

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2022-01-14 - 2026-07-31

Phase III

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites